Topical pharmacotherapy for allergic rhinitis: Nedocromil

Nedocromil sodium is a mast-cell stabilizer that prevents or ablates both the acute and late phases of the allergic response. It is an antiinflammatory agent that is not a steroid. It is more potent than the currently available mastcell stabilizer, cromolyn, and maintenance therapy may be possible a...

Descripción completa

Detalles Bibliográficos
Autor principal: Mabry, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 1993
Materias:
Current Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135241/
https://www.ncbi.nlm.nih.gov/pubmed/8285306
http://dx.doi.org/10.1016/0196-0709(93)90110-S
_version_ 1783518011173371904
author Mabry, Richard L.
author_facet Mabry, Richard L.
author_sort Mabry, Richard L.
collection PubMed
description Nedocromil sodium is a mast-cell stabilizer that prevents or ablates both the acute and late phases of the allergic response. It is an antiinflammatory agent that is not a steroid. It is more potent than the currently available mastcell stabilizer, cromolyn, and maintenance therapy may be possible at less frequent intervals than the initially recommended regimen of 4 times daily. Nedocromil for pulmonary administration is currently available. The nasal form has undergone clinical trials but has not yet been released in the United States.
format Online
Article
Text
id pubmed-7135241
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71352412020-04-08 Topical pharmacotherapy for allergic rhinitis: Nedocromil Mabry, Richard L. Am J Otolaryngol Current Review Nedocromil sodium is a mast-cell stabilizer that prevents or ablates both the acute and late phases of the allergic response. It is an antiinflammatory agent that is not a steroid. It is more potent than the currently available mastcell stabilizer, cromolyn, and maintenance therapy may be possible at less frequent intervals than the initially recommended regimen of 4 times daily. Nedocromil for pulmonary administration is currently available. The nasal form has undergone clinical trials but has not yet been released in the United States. Published by Elsevier Inc. 1993 2004-04-06 /pmc/articles/PMC7135241/ /pubmed/8285306 http://dx.doi.org/10.1016/0196-0709(93)90110-S Text en Copyright © 1993 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Current Review
Mabry, Richard L.
Topical pharmacotherapy for allergic rhinitis: Nedocromil
title Topical pharmacotherapy for allergic rhinitis: Nedocromil
title_full Topical pharmacotherapy for allergic rhinitis: Nedocromil
title_fullStr Topical pharmacotherapy for allergic rhinitis: Nedocromil
title_full_unstemmed Topical pharmacotherapy for allergic rhinitis: Nedocromil
title_short Topical pharmacotherapy for allergic rhinitis: Nedocromil
title_sort topical pharmacotherapy for allergic rhinitis: nedocromil
topic Current Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135241/
https://www.ncbi.nlm.nih.gov/pubmed/8285306
http://dx.doi.org/10.1016/0196-0709(93)90110-S
work_keys_str_mv AT mabryrichardl topicalpharmacotherapyforallergicrhinitisnedocromil

Ejemplares similares